Filtered By:
Drug: Flonase

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 103 results found since Jan 2013.

Mometasone/indacaterol (MF/IND) and mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) and FLU/SAL+tiotropium (TIO) in patients with inadequately controlled asthma: data from the PLATINUM program
Conclusion: MF/IND and MF/IND/GLY demonstrated clinical benefit vs widely used asthma treatments and represent novel o.d. treatment options for patients with inadequately controlled asthma
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Van Zyl-Smit, R., Chapman, K., Kerstjens, H., Gessner, C., Sagara, H., Tanase, A.-M., Hosoe, M., Shu, X., Pethe, A., Lawrence, D., Tillmann, H.-C., Mezzi, K., DAndrea, P. Tags: Airway pharmacology and treatment Source Type: research

Efficacy of the exhalation delivery system with fluticasone (EDS ‐FLU) in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgery
ConclusionsPatients with recurrent symptoms after sinus surgery who were treated with EDS-FLU demonstrated significant symptom and quality of life improvement. Unlike unoperated patients, patients with prior ESS had a numerically but not statistically greater response to the higher dose of EDS-FLU (2 sprays per nostril BID).This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - June 8, 2022 Category: Allergy & Immunology Authors: Randall A. Ow, Zachary M. Soler, Raj Sindwani, Donald A. Leopold, Jivianne T. Lee, Ramy A. Mahmoud, Joseph K. Han Tags: ORIGINAL ARTICLE Source Type: research

The Effect of EDS-FLU on Objective and Patient-Reported Subjective Outcomes for Patients with Chronic Rhinosinusitis with Nasal Polyps
CONCLUSIONS: Meaningful improvements were seen across multiple response criteria with EDS-FLU, suggesting that the broad treatment effect of EDS-FLU includes objective reduction in polyp grade and improvements in several patient-reported outcomes.TRIAL REGISTRATION: ClinicalTrials.gov (NAVIGATE I: NCT01622569 and NAVIGATE II: NCT01624662).PMID:35437059 | DOI:10.1177/01455613221088698
Source: Ear, Nose and Throat Journal - April 19, 2022 Category: ENT & OMF Authors: Randall A Ow John P McGinnis Harry J Sacks Mark E Mehle Source Type: research

Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study
Conclusion: IND/GLY/MF medium-dose o.d. delivered via a single inhaler was comparable in terms of symptom scores and rescue medication use, while resulting in better improvements in day-time symptoms and morning symptoms vs Sal/Flu high-dose b.i.d. + Tio o.d. delivered via two inhalers, at a reduced ICS dose.References:1.Rossi A. et al. Int J Chron Obstruct Pulmon Dis 2015;10:1383-92; 2.Kemp JP. et al. J Allergy Clin Immunol 2000;106:485-92
Source: European Respiratory Journal - October 28, 2020 Category: Respiratory Medicine Authors: Gessner, C., Kornmann, O., Maspero, J., Zyl-Smit, R. V., Krüll, M., Sojo, A., Salina, A., Gupta, P., Conde, L. G. Tags: Airway pharmacology and treatment Source Type: research

Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study
Conclusion: Both doses of MF/IND/GLY showed benefit in lung function and asthma exacerbations vs high-dose FLU/SAL independent of smoking history, indicating no effect of smoking history on efficacy of MF/IND/GLY.
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Kerstjens, H. A. M., Van Zyl-Smit, R., Chapman, K., Maspero, J., Hosoe, M., Tanase, A.-M., Lawrence, D., Pethe, A., Shu, X., Mezzi, K., D'Andrea, P. Tags: Airway pharmacology and treatment Source Type: research

Efficacy of once-daily medium- or high-dose mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus twice-daily high-dose fluticasone/salmeterol (FLU/SAL) to control nocturnal symptoms in patients (pts) with inadequately controlled asthma
Conclusion: Both doses of MF/IND/GLY taken once daily (a.m.) improved lung function and controlled symptoms throughout the day and during the night, more effectively than twice daily high-dose FLU/SAL.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Chapman, K. R., Van-Zyl Smit, R., Mezzi, K., Brittain, D., Kerstjens, H. A. Tags: 05.01 - Airway pharmacology and treatment Source Type: research

Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis
Conclusion: The patient characteristics analysed (age, age of asthma onset & BMI) do not significantly impact positive outcomes when using single inhaler o.d. IND/GLY/MF vs free combination of twice daily (b.i.d.) SAL/FLU & o.d. TIO. Therefore, treatment personalisation in terms of patient preference (e.g., convenience of o.d. vs b.i.d. regimen, single inhaler, device type) would be more appropriate.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Van Zyl-Smit, R., Lawrence, D., Mezzi, K., Brittain, D., Jaumont, X., Gessner, C. Tags: 05.01 - Airway pharmacology and treatment Source Type: research

P440 Exhalation delivery system with fluticasone (EDS-FLU) improves sleep in patients with CRS with nasal polyps
The majority of patients with CRS have poor quality of sleep which is associated with significantly worse quality of life scores and comorbid depression. EDS-FLU delivers intranasal steroid to superior/posterior sites of chronic rhinosinusitis inflammation where sinus ostia normally drain/ventilate and where polyps originate. EDS-FLU has recently been shown to improve primary symptoms, including nasal congestion and obstruction. This analysis examines the effect of EDS-FLU on sleep.
Source: Annals of Allergy, Asthma and Immunology - October 27, 2017 Category: Allergy & Immunology Authors: T. Murphy, J. Messina, J. Carothers, P. Djupesland, R. Mahmoud Source Type: research

P458 exhalation delivery system with fluticasone (eds-flu) improves outcomes regardless of baseline eosinophil count
Chronic rhinosinusitis with nasal polyps (CRSwNP), although commonly associated with Th2/eosinophilic inflammation, can also be characterized by Th1, Th3, or a combination. Corticosteroids inhibit multiple inflammatory pathways, eliciting broad immunosuppressive effects and well-characterized treatment responses. EDS-FLU improves outcomes in CRSwNP. This post-hoc analysis compared EDS-FLU response by baseline blood eosinophils to determine if there was a differential response to EDS-FLU among cohorts.
Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: S. Weinstein, D. Okhotin, H. Sacks, J. Messina Source Type: research

Efficacy of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of salmeterol/fluticasone (SAL/FLU) & tiotropium (TIO) in patients with uncontrolled asthma on prior LABA/ICS high-dose (GINA step 5): Results from ARGON study
Conclusion: In patients uncontrolled on LABA/ICS high-dose, efficacy of single inhaler IND/GLY/MF (high- and medium-dose) o.d. was similar to SAL/FLU high-dose b.i.d. & TIO o.d. via two different inhalers with two different dosing regimens, suggestive of potential clinical benefit of this treatment option over the current standard of care.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Gessner, C., Lawrence, D., Mezzi, K., Brittain, D., Van-Zyl Smit, R. Tags: 05.01 - Airway pharmacology and treatment Source Type: research

Effect of once daily (o.d.) mometasone/indacaterol/glycopyrronium (MF/IND/GLY) vs o.d. MF/IND and twice daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) with respect to age, age at asthma-onset and BMI at baseline: Subgroup analysis from IRIDIUM study
Conclusion: High-dose MF/IND/GLY provided similar benefits irrespective of baseline subgroups. Physicians looking to personalise treatment decision would be better served looking to pts preference factors (e.g., o.d./b.i.d. regimen, device type, availability of digital companion) than those clinical parameters explored here.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Kerstjens, H. A., Lawrence, D., Mezzi, K., Brittain, D., Jaumont, X., Chapman, K. R. Tags: 05.01 - Airway pharmacology and treatment Source Type: research

P441 Exhalation delivery system with fluticasone (EDS-FLU) improves peak nasal inspiratory flow (PNIF) in CRSWNP
Nasal polyps cause nasal passage obstruction in CRS leading to the defining symptoms: congestion/obstruction, rhinorrhea, facial pain/pressure, and decreased sense of smell/hyposmia. EDS-FLU was shown to substantially improve several objective and subjective measures in CRSwNP. In this analysis, we examined the effect of EDS-FLU on PNIF to assess nasal passage obstruction.
Source: Annals of Allergy, Asthma and Immunology - October 27, 2017 Category: Allergy & Immunology Authors: E. Schenkel, J. Messina, J. Carothers, P. Djupesland, R. Mahmoud Source Type: research

Exhalation Delivery System with Fluticasone (EDS-FLU) Improves Outcomes in Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in Patients With or Without Recent Intranasal Steroid Use
We report EDS-FLU treatment outcomes for CRSsNP patients with and without a recent INS.
Source: Journal of Allergy and Clinical Immunology - February 1, 2018 Category: Allergy & Immunology Authors: John C. Messina, Iftikhar Hussain, Jennifer L. Carothers, Emmanuel M. Mahlis, Ramy A. Mahmoud Source Type: research

Exhalation Delivery System with Fluticasone (EDS-FLU) Improves Health-Related Quality of Life (HRQoL) in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from NAVIGATE II
We report the effect of EDS-FLU on QoL as measured by the Rhinosinusitis Disability Index (RSDI).
Source: Journal of Allergy and Clinical Immunology - February 1, 2018 Category: Allergy & Immunology Authors: Shaila U. Gogate, John C. Messina, Jennifer L. Carothers, Per G. Djupesland, Ramy A. Mahmoud Source Type: research